No Data
No Data
Express News | Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Express News | Personalis 13D Filing Shows Tempus AI Reported A 15.1% Stake In The Co As Of July 3, 2024
Express News | Ravi Mhatre - Will Seek to Engage in Dialogue With Personalis’ Board and/or Management About Strategic Opportunities to Maximize Co's Shareholder Value
Express News | Personalis- Co, Foresight to Settle Litigation Pending in U.S. Federal District Court, Iprs Pending Before U.S. Ptab in Each Case Related to Patents
Express News | Personalis Inc - Personalis and Foresight Diagnostics Entered Into a Settlement and License Agreement
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $3.5
Needham analyst Michael Matson maintains $Personalis(PSNL.US)$ with a buy rating, and maintains the target price at $3.5.According to TipRanks data, the analyst has a success rate of 42.1% and a total